dr. dung le on biomarker for pd-1 agents in crc
Published 9 years ago • 1.6K plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
1:34
evolving role of pd-l1 as a biomarker
-
1:43
dr. topalian on biomarkers for anti- pd-1 therapies in melanoma
-
1:08
dr. suzanne l. topalian on immunotherapy biomarkers in crc
-
9:54
is the pd-l1 biomarker ready for prime time?
-
3:27
crc: emerging immunotherapy strategies in mss tumors
-
4:41
actively living with colorectal cancer: stephen's immunotherapy story
-
4:00
cancer immunotherapy - pd-1 and pd-l1
-
12:54
death to life with immunotherapy: stefanie's story
-
4:41
molecular testing for metastatic crc in 2020
-
5:48
emerging immunotherapy combinations in mss crc
-
1:07
dr. bendell on the next steps following progression on immunotherapy in msi-h crc
-
1:37
dr. o'neil discusses the development of biomarkers for crc
-
2:04
dr. bekaii saab on the role of immunotherapy in crc
-
9:02
pembrolizumab in msi-h crc tumors
-
1:31
dr. michael j. overman on immunotherapy in colorectal cancer
-
1:22
dr. kennedy on next steps with sirflox trial in liver-metastatic crc
-
6:45
activity of immunotherapy in the frontline setting
-
4:39
predictive value of ras mutations in metastatic colorectal cancer
-
9:24
msi status and immunotherapy in advanced colorectal cancer
-
8:39
prime trial: ras mutations defined in colorectal cancer
-
6:54
key takeaway 7: role of immunotherapy in msi-high mcrc
-
1:03
dr. overman on implications of tumor location data for patients with mcrc